SCHEMBL270656

SCHEMBL270656

B(Oc1ccc2ccccc2c1)Oc1ccc2ccccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 5/20 0.56
CYP1A2 P05177 3/20 0.56
AGXT P21549 2/20 0.50
TDP1 Q9NUW8 3/20 0.48
KDM4E B2RXH2 1/20 0.48
MAPK1 P28482 1/20 0.48
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
ALOX5 P09917 1/20 0.47
GAA P10253 1/20 0.45
RCE1 Q9Y256 1/20 0.45
GPR84 Q9NQS5 1/20 0.45
MAPT P10636 2/20 0.44
PTPN7 P35236 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 1/20 0.42
CYP3A4 P08684 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074881 0.91 ESR1 (0.50) CYP2A6CYP1A2AGXTTDP1KDM4E
SCHEMBL2510402 0.82 ESR1 (0.55) CYP2A6CYP1A2AGXTKDM4ECA1
SCHEMBL3684663 0.82 ESR1 (0.55) CYP2A6CYP1A2AGXTKDM4ECA1
SCHEMBL3437809 0.81 CYP1A2 (0.52) CYP2A6CYP1A2AGXTTDP1KDM4E
SCHEMBL3422941 0.81 ESR1 (0.52) CYP1A2CA1CA2CA9ALOX5
SCHEMBL3689307 0.79 HSD17B1 (0.53) CYP1A2KDM4ECA1CA2CA9
SCHEMBL3500443 0.78 CYP2A6 (0.67) CYP2A6CYP1A2AGXTTDP1KDM4E
SCHEMBL1403727 0.78 CYP1A2 (0.60) CYP2A6CYP1A2KDM4EMAPK1CA1
SCHEMBL1274301 0.76 CYP1A2 (0.50) CYP1A2TDP1MAPTMEN1KMT2A
SCHEMBL16241396 0.76 ALDH1A1 (0.50) CYP2A6CYP1A2AGXTTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11905237-B2 Access to chiral bisphenol (BPOL) ligands through desymmetrizing asymmetric ortho-selective mono-halogenation THE CHINESE UNIVERSITY OF HONG KONG (CN) 2024-02-20 US claimed
US-20210300853-A1 ACCESS TO CHIRAL BISPHENOL (BPOL) LIGANDS THROUGH DESYMMETRIZING ASYMMETRIC ORTHO-SELECTIVE MONO-HALOGENATION THE CHINESE UNIVERSITY OF HONG KONG (CN) 2021-09-30 US claimed
US-8921299-B2 Detergents having acceptable color THE PROCTER & GAMBLE COMPANY (US) 2014-12-30 US claimed
US-20070274922-A1 Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-11-29 US claimed
WO-2005024416-A1 WATER SOLUBLE BORONIC ACID FLUORESCENT REPORTER COMPOUNDS AND METHODS OF USE THEREOF WANG BINGHE (US) 2005-03-17 WO claimed
US-12522813-B2 Mannanase for formulations having pH 5-12 BASF SE (DE) 2026-01-13 US disclosed
EP-4148049-B1 ORGANIC LIGHT-EMITTING DEVICE COMPRISING ORGANIC LIGHT-EMITTING COMPOUND SFC CO LTD (KR) 2025-11-12 EP disclosed
US-12441713-B2 Organic compound and organic electroluminescent device comprising the same SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2025-10-14 US disclosed
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-10-07 US disclosed
US-20250311628-A1 PLURALITY OF HOST MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME DUPONT SPECIALTY MATERIALS KOREA LTD (KR) 2025-10-02 US disclosed
US-12389794-B2 Plurality of host materials and organic electroluminescent device comprising the same DUPONT SPECIALTY MATERIALS KOREA LTD. (KR) 2025-08-12 US disclosed
US-20250185453-A1 ORGANIC LIGHT-EMITTING DEVICE LG CHEM, LTD. (KR) 2025-06-05 US disclosed
US-6114361-A INHIBITORS OF MATRIX METALLOPROTEINASES AND REPROLYSIN; ADMINISTERING TO TREAT CONDITIONS WHICH CAN BE TREATED BY THE INHIBITION OF THESE ENZYMES PFIZER INC. (US) 2000-09-05 US disclosed
EP-1004578-A2 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives Pfizer Products Inc. (US) 2000-05-31 EP disclosed
WO-2000028331-A1 USE OF RADIOLIGANDS TO SCREEN INHIBITORS OF AMYLOID-BETA PEPTIDE PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2000-05-18 WO disclosed
WO-2000007995-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2000-02-17 WO disclosed
US-5767281-A Arthropodicidal oxazolines and thiazolines E. I. DU PONT DE NEMOURS AND COMPANY (US) 1998-06-16 US disclosed
US-5686393-A Arthropodicidal oxazolines and thiazolines E. I. DU PONT DE NEMOURS AND COMPANY (US) 1997-11-11 US disclosed
EP-0712394-A1 ARTHROPODICIDAL OXAZOLINES AND THIAZOLINES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1996-05-22 EP disclosed
WO-1995004726-A1 ARTHROPODICIDAL OXAZOLINES AND THIAZOLINES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1995-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12389794-B2 Plurality of host materials and organic electroluminescent device comprising the same TELO2, LIMS1, TERT CYP2A6 3916/4885CYP1A2 3356/4885AGXT 3327/4885
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 INMT, CARM1, KDM1B CYP2A6 3813/4885CYP1A2 1947/4885AGXT 3175/4885
US-20070274922-A1 Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof GUSB, BLVRB, BCL6 CYP2A6 2321/4885CYP1A2 4275/4885AGXT 658/4885
US-12441713-B2 Organic compound and organic electroluminescent device comprising the same ELAVL1, VDAC1, ELAVL3 CYP2A6 3599/4885CYP1A2 1886/4885AGXT 1454/4885
US-20250311628-A1 PLURALITY OF HOST MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME TELO2, LIMS1, TERT CYP2A6 3916/4885CYP1A2 3356/4885AGXT 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.